BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 8495805)

  • 1. Aldose reductase inhibition fails to prevent retinopathy in diabetic and galactosemic dogs.
    Engerman RL; Kern TS
    Diabetes; 1993 Jun; 42(6):820-5. PubMed ID: 8495805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retinal polyol and myo-inositol in galactosemic dogs given an aldose-reductase inhibitor.
    Kern TS; Engerman RL
    Invest Ophthalmol Vis Sci; 1991 Dec; 32(13):3175-7. PubMed ID: 1748548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Capillary basement membrane in retina, kidney, and muscle of diabetic dogs and galactosemic dogs and its response to 5 years aldose reductase inhibition.
    Engerman RL; Kern TS; Garment MB
    J Diabetes Complications; 1993; 7(4):241-5. PubMed ID: 8219367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aldose reductase and the development of renal disease in diabetic dogs.
    Kern TS; Engerman RL
    J Diabetes Complications; 1999; 13(1):10-6. PubMed ID: 10232704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Galactose-induced retinal microangiopathy in rats.
    Kern TS; Engerman RL
    Invest Ophthalmol Vis Sci; 1995 Feb; 36(2):490-6. PubMed ID: 7843917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The polyol pathway in retinal microangiopathy.
    Robison WG; Kinoshita JH; Kador PF
    Drugs; 1986; 32 Suppl 2():19-22. PubMed ID: 3098542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nerve conduction and aldose reductase inhibition during 5 years of diabetes or galactosaemia in dogs.
    Engerman RL; Kern TS; Larson ME
    Diabetologia; 1994 Feb; 37(2):141-4. PubMed ID: 8163047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of aldose reductase inhibition on nerve sorbitol and myoinositol concentrations in diabetic and galactosemic rats.
    Yue DK; Hanwell MA; Satchell PM; Handelsman DJ; Turtle JR
    Metabolism; 1984 Dec; 33(12):1119-22. PubMed ID: 6438438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hyperglycemia as a cause of diabetic retinopathy.
    Engerman RL; Kern TS
    Metabolism; 1986 Apr; 35(4 Suppl 1):20-3. PubMed ID: 3083205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aldose reductase activity and basement membrane thickening.
    Frank RN
    Metabolism; 1986 Apr; 35(4 Suppl 1):35-40. PubMed ID: 3083207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increases in collagen type IV and laminin in galactose-induced retinal capillary basement membrane thickening--prevention by an aldose reductase inhibitor.
    Das A; Frank RN; Zhang NL; Samadani E
    Exp Eye Res; 1990 Mar; 50(3):269-80. PubMed ID: 2108050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discordant effects of the aldose reductase inhibitor, sorbinil, on vascular structure and function in chronically diabetic and galactosemic rats.
    Tilton RG; Pugliese G; LaRose LS; Faller AM; Chang K; Province MA; Williamson JR
    J Diabet Complications; 1991; 5(4):230-7. PubMed ID: 1779018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glomerular polyol accumulation in diabetes and its prevention by oral sorbinil.
    Beyer-Mears A; Ku L; Cohen MP
    Diabetes; 1984 Jun; 33(6):604-7. PubMed ID: 6427041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aldose reductase inhibition and retinopathy.
    Robison WG
    Diabetes; 1994 Feb; 43(2):337-9. PubMed ID: 8288059
    [No Abstract]   [Full Text] [Related]  

  • 15. Retinal capillaries: basement membrane thickening by galactosemia prevented with aldose reductase inhibitor.
    Robison WG; Kador PF; Kinoshita JH
    Science; 1983 Sep; 221(4616):1177-9. PubMed ID: 6612330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ultrastructural localization of blood-retinal barrier breakdown in diabetic and galactosemic rats.
    Vinores SA; McGehee R; Lee A; Gadegbeku C; Campochiaro PA
    J Histochem Cytochem; 1990 Sep; 38(9):1341-52. PubMed ID: 2117624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention or moderation of some ultrastructural changes in the RPE and retina of galactosemic rats by aldose reductase inhibition.
    Vinores SA; Campochiaro PA
    Exp Eye Res; 1989 Sep; 49(3):495-510. PubMed ID: 2507341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of sorbinil, an aldose reductase inhibitor, on the corneal endothelium in galactosemic dogs.
    Datiles MB; Kador PF; Kashima K; Kinoshita JH; Sinha A
    Invest Ophthalmol Vis Sci; 1990 Nov; 31(11):2201-4. PubMed ID: 2122961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aldose reductase inhibitors and late complications of diabetes.
    Benfield P
    Drugs; 1986; 32 Suppl 2():43-55. PubMed ID: 3098544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of polyol pathway activity in diabetic and galactosemic rats by the aldose reductase inhibitor CP-45,634.
    Peterson MJ; Sarges R; Aldinger CE; MacDonald DP
    Adv Exp Med Biol; 1979; 119():347-56. PubMed ID: 115231
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.